Analgesic effects of chymase inhibitors in a model of cancer pain

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K18283
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 55050:Anesthesiology-related
• Research Institution: Osaka Medical and Pharmaceutical University
• Principal Investigator: KITANO MANABU 大阪医科薬科大学, 医学部, 助教 (10838296)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: キマーゼ

Outline of Final Research Achievements

Malignant tumors are currently the leading cause of death in Japan. Since many cancer patients experience pain, cancer pain control can improve quality of life. Cancer often metastasizes to the bone, causing local inflammation. Pain caused by bone metastases is considered to be difficult to control because of the complex relationship between nociceptive pain and neuropathic pain. Chymase has been studied for fibrosis in cardiovascular and various organs, but there are no reports on pain.
In this study, a mouse model of cancer pain was created and the pain effect was tested using TY51469, a chymase inhibitor, but no analgesic effect was obtained. Survival was followed over time, but the study failed to show an effect of TY51469 on survival.

Free Research Field

がん性疼痛

Academic Significance and Societal Importance of the Research Achievements

キマーゼががん性疼痛に作用するか検証を行うことで、がん性疼痛発現機序の解明につながり、がん患者のQOLの向上につながることに期待できる。
しかし、本研究ではキマーゼ阻害薬による鎮痛効果を検証することができず、がん性疼痛機序解明にはつながらなかった。